Viking Therapeutics, Inc. (1VT)
XETR
Real-time Data
07:00 AM
Day's Range
22.7052 wk Range
22.70Overview - 1VT - Viking Therapeutics, Inc.
Key Statistics
Valuation
Enterprise Value
1.98B
P/E (Trailing)
‪-7.31‬
Price / Book
‪7.49‬
EV / EBITDA
‪-5.04‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-51.86%‬
Return on Equity
‪-88.85%‬
Ownership
Shares Outstanding
116.65M
Float
113.73M
Held by Insiders
‪2.83%‬
Held by Institutions
‪60.47%‬
Price stats
Beta
‪0.64‬
50-Day Avg
‪27.91‬
200-Day Avg
‪27.91‬
Market Cap - 1VT - Viking Therapeutics, Inc.
Peers - 1VT - Viking Therapeutics, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on XETR.
- 1VTXETRViking Therapeutics, Inc.2.96BMarket Cap-9.42%52-week change-7.32P/E (Trailing)‪0.00%‬Profit Margin
- ANLXETRAnalog Devices, Inc.174.68BMarket Cap+43.92%52-week change50.21P/E (Trailing)‪29.78%‬Profit Margin
- 0QFXETRModerna Inc.74.96BMarket Cap+87.33%52-week change-25.86P/E (Trailing)‪-141.42%‬Profit Margin
- 22UAXETRBioNTech SE American Depositary Share21.34BMarket Cap-7.23%52-week change157.87P/E (Trailing)‪-63.63%‬Profit Margin
- BBZAXETRBB Biotech AG3.29BMarket Cap+42.63%52-week change13.32P/E (Trailing)‪127.31%‬Profit Margin
- BV3XETRBavarian Nordic A/S2.18BMarket Cap-8.37%52-week change11.17P/E (Trailing)‪24.33%‬Profit Margin
- 22ZXETRZealand Pharma A/S2.01BMarket Cap-98.82%52-week change6.33P/E (Trailing)‪59.02%‬Profit Margin
Profile Summary - 1VT - Viking Therapeutics, Inc.
About
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. Viking Therapeutics is advancing a pipeline that includes VK2735, a dual GLP-1/GIP receptor agonist being studied in oral and injectable forms for obesity and other metabolic…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
